

# Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy:  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  
 1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+  Maintenance

ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

**Biomarkers/Characteristics:** (Select all that apply)

ALK Status:  Negative  Positive  Not Reported

MET Amplification:  Negative  Positive  Not Reported

EGFR:  Negative  Positive  Not Reported

RET Gene Rearrangement:  Absent  Present  Not Reported

BRAF:  V600E Mutation  V600K Mutation  
 Wild Type  Not Reported

ROS1 Rearrangement:  Negative  Positive  Not Reported

## Limited Stage | Primary, Adjuvant, or First Line of Therapy (1<sup>st</sup> Line)

Carboplatin and etoposide (Toposar) ± XRT

Cisplatin and etoposide (Toposar) ± XRT

## Extensive Stage | First Line of Therapy (1<sup>st</sup> Line)

Carboplatin and etoposide (Toposar)

## Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | Relapse Greater than Six (6) Months

Carboplatin and etoposide (Toposar)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

